Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 9/20 | 0.66 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | BCR | P11274 | 2/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15618209 | 0.91 | MKNK1 (0.55) | MKNK1GRM4SYK | |
| SCHEMBL15618440 | 0.87 | MKNK1 (0.51) | MKNK1GRM4SYKGRIN2DGRIN3B | |
| SCHEMBL15618507 | 0.84 | MKNK1 (0.49) | MKNK1GRM4BRAFTNNI3KSYK | |
| SCHEMBL17026093 | 0.84 | MKNK1 (0.49) | MKNK1GRM4BRAFTNNI3KSYK | |
| SCHEMBL15618290 | 0.84 | MKNK1 (0.55) | MKNK1BRAFTNNI3KSYK | |
| SCHEMBL28105784 | 0.83 | MKNK1 (0.46) | MKNK1GRM4BRAFTNNI3KSYK | |
| SCHEMBL15618402 | 0.82 | MKNK1 (0.46) | MKNK1 | |
| SCHEMBL15618498 | 0.81 | MKNK1 (0.64) | MKNK1GRM4ABL1BCRSYK | |
| SCHEMBL17034053 | 0.80 | MKNK1 (0.46) | MKNK1GRM4BRAFTNNI3KGRIN2D | |
| SCHEMBL17034024 | 0.80 | MKNK1 (0.46) | MKNK1GRM4BRAFTNNI3KGRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2897957-B1 | SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS | Bayer Pharma AG (DE) | 2016-10-26 | — | — | EP | claimed |
| EP-2897957-B1 | SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS | Bayer Pharma AG (DE) | 2016-10-26 | — | — | EP | disclosed |
| US-9382255-B2 | Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-05 | — | — | US | disclosed |
| US-9382255-B2 | Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-05 | — | — | US | disclosed |
| US-20150239891-A1 | SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-27 | — | — | US | disclosed |
| US-20150239891-A1 | SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-27 | — | — | US | disclosed |
| EP-2897957-A1 | SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2015-07-29 | — | — | EP | disclosed |
| WO-2014044691-A1 | SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239891-A1 | SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS | MKNK1, MKNK2, MAP3K20 | MKNK1 1/4885GRM4 3838/4885ABL1 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.